Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd.
Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, Nagai T, Ohnishi K, Maeda Y, Matsuda A, Amagasaki T, Yanada M. Nakamae H, et al. Among authors: shibayama h. Int J Hematol. 2011 May;93(5):624-632. doi: 10.1007/s12185-011-0841-8. Epub 2011 Apr 27. Int J Hematol. 2011. PMID: 21523338 Clinical Trial.
Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation study.
Ogata K, Kakumoto K, Matsuda A, Tohyama K, Tamura H, Ueda Y, Kurokawa M, Takeuchi J, Shibayama H, Emi N, Motoji T, Miyazaki Y, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F. Ogata K, et al. Among authors: shibayama h. Leuk Res. 2012 Oct;36(10):1229-36. doi: 10.1016/j.leukres.2012.05.006. Epub 2012 Jun 7. Leuk Res. 2012. PMID: 22682984
Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.
Ueda Y, Mizutani C, Nannya Y, Kurokawa M, Kobayashi S, Takeuchi J, Tamura H, Ogata K, Dan K, Shibayama H, Kanakura Y, Niimi K, Sasaki K, Watanabe M, Emi N, Teramura M, Motoji T, Kida M, Usuki K, Takada S, Sakura T, Ito Y, Ohyashiki K, Ogawa H, Suzuki T, Ozawa K, Imai K, Kasai M, Hata T, Miyazaki Y, Morita Y, Kanamaru A, Matsuda A, Tohyama K, Koga D, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F. Ueda Y, et al. Among authors: shibayama h. Leuk Lymphoma. 2013 Jul;54(7):1450-8. doi: 10.3109/10428194.2012.745074. Epub 2012 Nov 26. Leuk Lymphoma. 2013. PMID: 23110324
Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma.
Kobayashi T, Kuroda J, Fuchida S, Kaneko H, Yagi H, Shibayama H, Tanaka H, Kosugi S, Uoshima N, Kobayashi M, Adachi Y, Ohta K, Ishii K, Uchiyama H, Matsuda M, Nakatani E, Tsudo M, Shimazaki C, Takaori-Kondo A, Nomura S, Matsumura I, Taniwaki M, Kanakura Y; KMF investigators. Kobayashi T, et al. Among authors: shibayama h. Int J Hematol. 2015 Jan;101(1):37-45. doi: 10.1007/s12185-014-1696-6. Epub 2014 Nov 11. Int J Hematol. 2015. PMID: 25385278
Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.
Kobayashi S, Ueda Y, Nannya Y, Shibayama H, Tamura H, Ogata K, Akatsuka Y, Usuki K, Ito Y, Okada M, Suzuki T, Hata T, Matsuda A, Tohyama K, Kakumoto K, Koga D, Mitani K, Naoe T, Sugiyama H, Takaku F. Kobayashi S, et al. Among authors: shibayama h. Cancer Biomark. 2016 Mar 31;17(1):21-32. doi: 10.3233/CBM-160612. Cancer Biomark. 2016. PMID: 27062571
Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan.
Takenaka K, Shimoda K, Uchida N, Shimomura T, Nagafuji K, Kondo T, Shibayama H, Mori T, Usuki K, Azuma T, Tsutsumi Y, Tanaka J, Dairaku H, Matsuo K, Ozawa K, Kurokawa M, Arai S, Akashi K. Takenaka K, et al. Among authors: shibayama h. Int J Hematol. 2017 Jan;105(1):59-69. doi: 10.1007/s12185-016-2102-3. Epub 2016 Oct 19. Int J Hematol. 2017. PMID: 27761702
Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.
Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, Matsumura I, Matsuda A, Aoki M, Ito K, Shibayama H. Nakamae H, et al. Among authors: shibayama h. Int J Hematol. 2018 Mar;107(3):327-336. doi: 10.1007/s12185-017-2353-7. Epub 2017 Oct 26. Int J Hematol. 2018. PMID: 29076005
Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).
Ishikawa J, Matsumura I, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Matsuoka KI, Shibayama H, Hino M, Hirase C, Kamimura T, Shimose T, Akashi K, Kanakura Y. Ishikawa J, et al. Among authors: shibayama h. Int J Hematol. 2018 May;107(5):535-540. doi: 10.1007/s12185-018-2401-y. Epub 2018 Jan 23. Int J Hematol. 2018. PMID: 29362980 Clinical Trial.
Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
Matsumura-Kimoto Y, Kuroda J, Kaneko H, Kamitsuji Y, Fuchida SI, Nakaya A, Shibayama H, Uoshima N, Yokota I, Uchiyama H, Yagi H, Kosugi S, Matsui T, Ishikawa J, Matsuda M, Ohta K, Iida M, Tanaka H, Kobayashi M, Wada K, Shimazaki C, Nomura S, Imada K, Hino M, Matsumura I, Kanakura Y, Takaori-Kondo A; Kansai Myeloma Forum Investigators. Matsumura-Kimoto Y, et al. Among authors: shibayama h. Int J Hematol. 2018 May;107(5):541-550. doi: 10.1007/s12185-018-2416-4. Epub 2018 Jan 29. Int J Hematol. 2018. PMID: 29380179
267 results